Karyopharm Therapeutics Inc. News
Staggering Moves: Cramer's 'Mad Money' Recap (Monday 8/24/20)
Extreme valuations may be disturbing, Jim Cramer says, but Apple and Tesla are not expensive, per se, if everything goes right.
Biotech Stocks Post Double-Digit Gains in Monday Surge
Biotech stocks soared Monday amid takeover speculation and a slew of positive drug research test results.
Magellan Midstream, Xylem, Boston Scientific: 'Mad Money' Lightning Round
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers
Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.
What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)
Earnings and Fed speakers are on tap in the next few days.
Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Tips for Retirees to Deal with Falling Stocks and Bonds
The markets' slide particularly hurts retirees, who may have to sell some of their stocks and bonds to finance spending.
Alphabet CEO Pichai Continues to Sound Alarm About the Economy
The parent company of Google and Youtube is preparing for a sharp deterioration in the health of the economy.